Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions

NCT ID: NCT06720207

Last Updated: 2025-06-27

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 30 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-07-01
• Study Completion Date: 2027-07-31

Brief Summary

In this study, the investigators intend to utilize 68Ga-Pentixafor Positron Emission Tomography（PET） imaging for patients diagnosed with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The investigators will compare the imaging results with those obtained from 18F-FDG imaging, and a correlation analysis will be performed to assess progression-free survival among patients. This analysis aims to evaluate the diagnostic efficacy and the potential for early prediction of treatment efficacy associated with 68Ga-Pentixafor in these specific conditions.

Detailed Description

The hematolymphatic system comprises blood, lymph nodes, extranodal lymphatic tissues, bone marrow, and the spleen. When malignant transformations occur within this system, they often infiltrate various tissues and organs throughout the body. Therefore, a comprehensive assessment of all tissues and organs is necessary to delineate the lesions' extent and conduct clinical staging to guide treatment. Lymphoma is the most prevalent malignancy of the hematologic system, with non-Hodgkin lymphoma (NHL) accounting for a significant incidence within this category, representing approximately 90% of lymphomas in our country. The clinical classification of NHL is complex, exhibiting considerable heterogeneity in biological behavior, immunophenotyping, and prognosis. The main subtypes include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), T-cell lymphoma (TCL), marginal zone lymphomas (MZL), and mantle cell lymphoma (MCL). Multiple myeloma (MM) is a malignant disease characterized by the clonal proliferation of abnormal plasma cells and is the second most common hematologic malignancy following lymphoma. Common symptoms include organ dysfunction related to myeloma, encapsulated in the "CRAB" criteria-hypercalcemia, renal insufficiency, anemia, and bone disease-along with manifestations of organ damage due to amyloidosis. The prognosis is poor if patients do not receive timely and effective treatment.

Chemokine receptor 4 (CXCR4) is a member of the C-X-C motif (CXC) subfamily of chemokine receptors and is widely expressed in various types of organ tissue. It significantly regulates numerous physiological processes through interaction with CXC-chemokine ligand 12 (CXCL12). The CXCR4/CXCL12 biological axis is critical in the proliferation, invasion, and metastasis of NHL and MM and is considered a marker of poor prognosis. Recently, a new positron emission tomography (PET) tracer targeting CXCR4, 68Ga-Pentixafor, has been developed and is being increasingly utilized to diagnose hematological malignancies. The 68Ga-Pentixafor PET demonstrates notable advantages in identifying lymphoma, particularly indolent types, as well as in detecting early small lesions associated with MM. It shows greater sensitivity compared to 18F-fluorodeoxyglucose (FDG) imaging. This advancement not only enhances patient diagnosis and efficacy evaluation but also functions as a biological targeting molecule for individuals with poor prognostic outcomes, enabling these patients to access more intensive treatment options.

18F-fluorodeoxyglucose (FDG) is the most widely used tracer in nuclear medicine for tumor imaging, applicable to the initial staging and efficacy assessment of the vast majority of tumors. According to the 2021 guidelines from the Chinese Medical Association's Nuclear Medicine Branch and recommendations from the International Myeloma Working Group (IMWG), 18F-FDG positron emission tomography / computed tomography (PET/CT) imaging is recommended for the diagnostic and therapeutic management of all lymphoma and MM patients. However, it is important to note that the uptake of FDG in NHL is related to its pathological type; DLBCL and FL typically exhibit high FDG uptake, while MZL, MCL, and small lymphocytic lymphoma(SLL) usually show moderate to low FDG uptake. This variability results in differences in the diagnostic accuracy of 18F-FDG PET depending on the subtype of NHL. Additionally, approximately 11% of MM patients may present with false-negative FDG imaging, which could be attributed to factors such as small lesion size, a lower proliferation rate of clonal plasma cells, or hexokinase deficiency. Furthermore, physiological or inflammatory uptake of 18F-FDG can sometimes interfere with the detection of MM lesions.

In summary, early diagnosis before treatment, precise staging, and post-treatment prognostic stratification, as well as the detection of residual tumor metabolic activity, represent significant challenges in the diagnosis and treatment of NHL and MM. The use of 68Ga-pentixafor PET/MR allows for non-invasive visualization of CXCR4 expression in vivo, demonstrating high sensitivity for NHL and MM with low FDG uptake. This capability enhances diagnostic accuracy and facilitates precise staging, contributing to the development of personalized treatment plans and ultimately improving patient outcomes. Through the implementation of this project, the investigators aim to introduce new technologies in the management of NHL and MM patients, providing more effective diagnostic and therapeutic options.

Conditions

Non Hodgkin's Lymphoma; Multiple Myeloma (MM)

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Research group

It is expected to include 30 newly diagnosed NHL or MM patients, and the tracer radiation used in the study is extremely small and will not have any physiological effects on the subjects.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. Age of 18 years or older

2. ECOG < 2

3. Newly diagnosed patients with NHL and MM who have been confirmed or are highly suspected based on pathological examination

4. Completion of 18F-FDG PET/CT or PET/MR imaging within the past week in our department

Exclusion Criteria

1. Pregnant and breastfeeding women;

2. Individuals with severe hepatic and renal failure;

3. Patients with concurrent malignancies;

4. Individuals unable to remain supine for a duration of 30 minutes to complete the examination;

5. Patients with diagnosed claustrophobia;

6. Patients containing metallic implants;

7. Individuals deemed unsuitable for participation in clinical trials by researchers.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai East Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Jie Ding, MD

Role: CONTACT

dingjie940406@163.com

086-38804518

Other Identifiers

SEH-2024210

Identifier Type: -

Identifier Source: org_study_id